Tuesday, April 10, 2012
RedHill Biopharma Ltd., of Tel Aviv, Israel, said initial analysis of a pharmacokinetic study comparing its version of odansetron with Zofran (odansetron, GlaxoSmithKline plc) showed the trial met its objective of establishing bioequivalence. Assuming the final clinical study report supports the preliminary findings, RedHill said it will consider filing for U.S. marketing approval.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.